|
|
Delcath Systems Inc (NASDAQ: DCTH) |
|
Price: $16.4800
$0.00 
0.000%
|
| Day's High:
| $16.489999771118164
| Week Perf:
| 0.12 %
|
| Day's Low: |
$ 16.25 |
30 Day Perf: |
6.53 % |
| Volume (M): |
180,800 |
52 Wk High: |
$ 17.42 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$11.10 |
| Open: |
$16.32 |
52 Wk Low: |
$8.12 |
|
|
| Market Capitalization (Millions $) |
655 |
| Shares
Outstanding (Millions) |
40 |
| Employees |
156 |
| Revenues (TTM) (Millions $) |
94 |
| Net Income (TTM) (Millions $) |
1 |
| Cash Flow (TTM) (Millions $) |
29 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Delcath Systems Inc is a medical technology company that specializes in the development and commercialization of products and therapies for the treatment of cancer. The company's main focus is on precision-targeted, whole organ chemotherapy, known as the Delcath Hepatic CHEMOSAT Delivery System. This system is designed to deliver high-dose chemotherapy directly to the liver while minimizing exposure to the rest of the body, thereby reducing toxic side effects. Delcath Systems Inc aims to improve patient outcomes and provide physicians with innovative treatment options for liver metastases.
Company Address: 566 Queensbury Avenue Queensbury 12804 NY
Company Phone Number: 743-8892 Stock Exchange / Ticker: NASDAQ DCTH
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Tue, Sep 23 2025 3:28 AM UTC
Targeting Liver Tumors: Delcath Systems Promising Developments in Oncology Delcath Systems, Inc., a leader in the field of interventional oncology, has made significant strides in the ongoing battle against primary and metastatic liver cancers. As the 2025 European Society for Medical Oncology (ESMO) Congress unfolds, Delcath s recent achievements underline the company s pi...
|
| Business Update
Published Sat, Jul 26 2025 4:39 AM UTC
In a significant move aimed at bolstering its growth and operational capabilities, Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering interventional oncology company focused on innovative treatments for primary and metastatic cancers of the liver, has announced the grant of equity awards as inducements to new hires. This decision reflects the company s ongoing commitment to ...
|
| Business Update
Published Mon, Sep 23 2024 3:58 AM UTC
QUEENSBURY, N.Y. Delcath Systems, Inc. (Nasdaq: DCTH) continues to demonstrate its commitment to fostering industry-leading talent as part of its broader strategy to advance treatments for primary and metastatic liver cancers. The interventional oncology company recently announced inducement grants under Nasdaq Listing Rule 5635(c)(4), signifying a strategic move to attra...
|
| Business Update
Published Sat, Sep 21 2024 12:47 AM UTC
Delcath Systems, Inc.: Advancements in Liver Cancer Treatment and Strategic Employment Inducements Delcath Systems, Inc. (NASDAQ: DCTH), based in Queensbury, New York, is carving a significant niche in the interventional oncology field, particularly focused on therapies targeting primary and metastatic cancers of the liver. Recent announcements from the company highlight its...
|
| Business Update
Published Fri, Sep 20 2024 8:47 PM UTC
QUEENSBURY, N.Y. In an assertive move to bolster its talented roster, Delcath Systems, Inc. (Nasdaq: DCTH), a leading interventional oncology company dedicated to the treatment of primary and metastatic cancers of the liver, disclosed the issuance of three distinct equity awards to new employees as part of its strategic growth plan. These inducement grants, sanctioned by t...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0.04 $ |
| Revenues (TTM) |
2.37 $
|
| Cash Flow (TTM) |
0.72 $ |
| Cash |
2.41 $
|
| Book Value |
3.05 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
602,936 |
| Net
Income per Employee (TTM) |
3,410 |
| Receivable Turnover Ratio (TTM) |
6.77 |
| Inventory Turnover Ratio (TTM) |
1.16 |
| Asset Turnover Ratio (TTM) |
0.74 |
|
|
| Per Share |
|
| Earnings (TTM) |
0.04 $
|
| Revenues (TTM) |
2.37 $ |
| Cash Flow (TTM) |
0.72 $ |
| Cash |
2.41 $
|
| Book Value |
3.05 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| CHEMOSAT |
|
 12.77 % |
of total Revenue |
| HEPZATO KIT |
|
173.03 % |
of total Revenue |
| Non-US |
|
12.77 % |
of total Revenue |
| United States |
|
173.03 % |
of total Revenue |
| |
On January 13 2025 the Delcath Systems Inc provided following guidance
nnDelcath Systems Inc. Provides Preliminary Financial Results for Fourth Quarter and Full Year 2024nn
QUEENSBURY, N.Y. - Delcath Systems, Inc. (Nasdaq: DCTH), an innovative interventional oncology company dedicated to the treatment of primary and metastatic liver cancers, has released its preliminary financial results for the fourth quarter and the entire fiscal year ending December 31, 2024. According to the estimates, the company anticipates generating approximately $15.1 million in revenue for the fourth quarter, with full-year revenue projected at around $37.2 million.
These figures represent a significant indicator of the company's ongoing efforts to address the challenges posed by liv...
|
|
|
